title: Response to the letter by Dr Chin and co-workers.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Härtter
authors.forename: Michael
authors.initials: M
authors.lastname: Koenen-Bergmann
authors.forename: Ashish
authors.initials: A
authors.lastname: Sharma
authors.forename: Gerhard
authors.initials: G
authors.lastname: Nehmiz
authors.forename: Ute
authors.initials: U
authors.lastname: Lemke
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Timmer
authors.forename: Paul A
authors.initials: PA
authors.lastname: Reilly
mesh_terms: D001562:Benzimidazoles / Q000493:pharmacokinetics*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D011725:Pyridines / Q000493:pharmacokinetics*; D012293:Rifampin / Q000494:pharmacology*
chemical_list: D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D011725:Pyridines; D012293:Rifampin